pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ivonescimab · news · pharmadog
← back to ivonescimab
News mentioning ivonescimab
30
stories
15h
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
1d
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
3d
Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
endpoints
3d
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
8d
Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in China
raps
22d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
24d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
27d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
29d
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
29d
STAT+: Pharma tries to tamp down broad China restrictions
stat
29d
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
biopharma dive
29d
Summit reports two-year survival data for Western patients, though context lacking
endpoints
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 11, 26
Summit pulls $500M share sale a day after announcing it
biopharma dive
Jun 5, 26
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
biopharma dive
Jun 1, 26
STAT+: A turning point for pancreatic cancer patients
stat
Jun 1, 26
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
stat
May 31, 26
STAT+: A standing ovation for RevMed, and caution for Akeso
stat
May 31, 26
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
stat
May 31, 26
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
stat
May 31, 26
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
stat
May 31, 26
STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
stat
May 31, 26
Akeso, Summit drug extends survival in closely watched lung cancer trial
biopharma dive
May 30, 26
STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
stat
May 8, 26
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
onclive
May 7, 26
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
onclive
May 1, 26
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
biopharma dive
May 1, 26
Summit slips on ivonescimab's apparent interim miss in sign of investor frustration
endpoints
Apr 30, 26
STAT+: What does Akeso’s primo plenary spot say about its survival data?
stat
